| oxaliplatin / Generic mfg. |
NCT00142480: Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer |
|
|
| Completed | 2 | 8 | US | Capecitabine, Oxaliplatin, Bevacizumab, Radiation therapy | Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, Genentech, Inc., Sanofi-Synthelabo, Hoffmann-La Roche | Biliary Tract Cancer, Gallbladder Adenocarcinoma | 07/07 | 04/11 | | |
NCT00193609: Oxaliplatin and Capecitabine in the Treatment of Relapsed/Refractory Carcinoma of Unknown Primary Site |
|
|
| Completed | 2 | 48 | US | Oxaliplatin, Eloxatin, Capecitabine, Xeloda | SCRI Development Innovations, LLC, Roche Pharma AG, Sanofi-Synthelabo | Neoplasms, Unknown Primary | 04/08 | 01/09 | | |
NCT00354887: Capecitabine and Oxaliplatin in Adenocarcinoma of the Small Bowel and Ampulla of Vater |
|
|
| Completed | 2 | 31 | US | Capecitabine, Xeloda, Oxaliplatin, Eloxatin | M.D. Anderson Cancer Center, Sanofi-Synthelabo | Gastrointestinal Cancer | 11/09 | 11/09 | | |
NCT00127036: Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) |
|
|
| Terminated | 2 | 65 | US | XELOX, Oxaliplatin and Capecitabine, XELIRI, Irinotecan and Capecitabine, Bevacizumab, Avastin® | H. Lee Moffitt Cancer Center and Research Institute, Roche Pharma AG | Adenocarcinoma, Colon Cancer | 12/10 | 12/10 | | |
NCT00418093: Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma |
|
|
| Terminated | 2 | 19 | US | Gemcitabine, Oxaliplatin, Bevacizumab | Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital, Eli Lilly and Company, Sanofi-Synthelabo, Genentech, Inc. | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | 01/11 | 10/11 | | |
NCT00591149: Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer |
|
|
| Terminated | 2 | 16 | US | Oxaliplatin, Eloxatin, Docetaxel, Taxotere, Cetuximab, Erbitux | University of Kansas Medical Center, Sanofi | Head and Neck Cancer, Carcinoma, Squamous | 04/12 | 04/12 | | |
NCT00707889 / 2007-007081-38: Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer |
|
|
| Completed | 2 | 159 | US, Canada, Europe, RoW | ABT-869, bevacizumab, oxaliplatin, mFOLFOX6 regimen, folinic acid, fluorouracil | AbbVie (prior sponsor, Abbott), Genentech, Inc. | Advanced Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum | 05/12 | 05/12 | | |
|
|
NCT00816543: Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma |
|
|
| Completed | 2 | 41 | RoW | DOCETAXEL, S-1, OXALIPLATIN | Sanofi | Gastric Cancer | 05/12 | 05/12 | | |
NCT01703910 / 2012-001307-20: Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
|
|
| Completed | 2 | 29 | Europe | Arm A chemotherapy, Capecitabine, Cisplatin, Cetuximab, Doxorubicin, Fluorouracil, Gemcitabine, Irinotecan, Topotecan, Mitomycin C, Oxaliplatin, Paclitaxel, Docetaxel, Pemetrexed, Raltitrexed, Sorafenib, Erlotinib, Vinorelbine, Dasatinib, Etoposide, arm B chemotherapy | Centro Nacional de Investigaciones Oncologicas CARLOS III, Hospital Universitario de Fuenlabrada, Grupo Hospital de Madrid, Apices Soluciones S.L. | Adenocarcinoma of Colon, Adenocarcinoma of Rectum, Metastatic Disease | 11/12 | 12/14 | | |
NCT02195180 / 2013-004262-34: Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma |
|
|
| Completed | 2 | 141 | Europe | ERY001, L asparaginase encapsulated in erythrocytes, Gemcitabine, 5-fluoro-uracil/oxaliplatin/leucovorin (folfox) | ERYtech Pharma | Pancreatic Adenocarcinoma Metastatic | 02/17 | 11/17 | | |
IXOGoo1, NCT01129310: First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer. |
|
|
| Completed | 2 | 47 | Canada | Irinotecan-Capecitabine-Oxaliplatin, Camptosar; Xeloda; Eloxatin | AHS Cancer Control Alberta, Sanofi | Gastrointestinal Neoplasm, Gastric Adenocarcinoma | 05/18 | 05/18 | | |
NCT00526110: Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients |
|
|
| Completed | 1/2 | 98 | US | 5-Fluorouracil, 5-FU, Adrucil, Efudex, Docetaxel, Taxotere, Oxaliplatin, Eloxatin | M.D. Anderson Cancer Center, Sanofi-Synthelabo | Gastrointestinal Diseases | 06/15 | 06/15 | | |
